Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Decock

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Clinical Chemistry|June 27, 2006
How accurate is the antiprimer quenching-based real-time PCR for detection of Her2/neu in clinical cancer samples?Julie Decock
Molecular Oncology|May 29, 2021
Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapyAdviti Naik, Julie Decock
Frontiers in Oncology|December 16, 2020
Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast TumorsAdviti Naik, Julie Decock
Cancers|July 18, 2019
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?Ghaneya Al-Khadairi, Julie Decock
Frontiers in Oncology|June 16, 2023
Editorial: Tumor microenvironment, inflammation, and resistance to immunotherapiesJulie Decock, Giuseppina Comito, Apostolos Zaravinos
Frontiers in Oncology|November 28, 2022
Editorial: Cancer testis antigens in cancer: Recent developments as cancer biomarkers and therapeutic targetsAdviti Naik, Joe Yeong, Julie Decock
Frontiers in Immunology|April 1, 2026
Editorial: Unraveling breast cancer complexity: insights from single-cell sequencing and spatial transcriptomicsApriliana E R Kartikasari, Julie Decock
Current Opinion in Oncology|October 15, 2005
Proteases and metastasis: clinical relevance nowadays?Julie Decock, Robert Paridaens, Tanja Cufer
Frontiers in Oncology|March 15, 2021
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future ProspectsRemy Thomas, Ghaneya Al-Khadairi, Julie Decock
Frontiers in Genetics|March 4, 2024
Editorial: Cancer genomics in the era of precision medicineOmar M Khan, Domenico Mallardo, Julie Decock
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Clinical Chemistry|June 27, 2006
How accurate is the antiprimer quenching-based real-time PCR for detection of Her2/neu in clinical cancer samples?Julie Decock
Molecular Oncology|May 29, 2021
Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapyAdviti Naik, Julie Decock
Frontiers in Oncology|December 16, 2020
Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast TumorsAdviti Naik, Julie Decock
Cancers|July 18, 2019
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?Ghaneya Al-Khadairi, Julie Decock
Frontiers in Oncology|June 16, 2023
Editorial: Tumor microenvironment, inflammation, and resistance to immunotherapiesJulie Decock, Giuseppina Comito, Apostolos Zaravinos
Frontiers in Oncology|November 28, 2022
Editorial: Cancer testis antigens in cancer: Recent developments as cancer biomarkers and therapeutic targetsAdviti Naik, Joe Yeong, Julie Decock
Frontiers in Immunology|April 1, 2026
Editorial: Unraveling breast cancer complexity: insights from single-cell sequencing and spatial transcriptomicsApriliana E R Kartikasari, Julie Decock
Current Opinion in Oncology|October 15, 2005
Proteases and metastasis: clinical relevance nowadays?Julie Decock, Robert Paridaens, Tanja Cufer
Frontiers in Oncology|March 15, 2021
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future ProspectsRemy Thomas, Ghaneya Al-Khadairi, Julie Decock
Frontiers in Genetics|March 4, 2024
Editorial: Cancer genomics in the era of precision medicineOmar M Khan, Domenico Mallardo, Julie Decock
Pageof 6